Stryker (SYK)

Healthcare · Medical Devices · S&P 500
$278.20 -2.46% on the day Market cap $112.2B 52-week range $267.00 to $392.55 Prices as of Oct 7, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Free cash flow growth the price needs
9% a year for 10 years

At a market value of $112.2B, Stryker's free cash flow of $4.3B (fiscal 2025) would need to grow about 9% a year for the stock to be worth today's price. That is slower than the company has grown its free cash flow over the last 9 years.

Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from Stryker's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.

Implied by the price8.5% a year
Free cash flow, last 9 years13.0% a year
Revenue, same period9.3% a year
Price to free cash flow26.2x

Fundamental grade

B

Five factors scored 1 to 9 from SYK's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation5
Profitability7
Growth7
Financial health6
Cash efficiency7

Key numbers

P/E (trailing)28.8x
P/E (forward)18.8x
Price / free cash flow26.2x
EV / EBITDA16.3x
Price / sales4.34x
Price / book4.71x
Revenue growth+9.4%
Operating margin21.4%
Net margin14.4%
Return on equity15.6%
Dividend yield1.2%
Debt / equity1.00x

Results from SEC filings

Fiscal years, from Stryker's 10-K filings. The deep dive has 15+ years, quarters and every line.

Fiscal year20212022202320242025
Revenue$17.1B$18.4B$20.5B$22.6B$25.1B
Net income$2.0B$2.4B$3.2B$3.0B$3.2B
Free cash flow$2.7B$2.0B$3.1B$3.5B$4.3B
EPS (diluted)$5.21$6.17$8.25$7.76$8.40
Operating margin15.1%15.4%19.0%16.3%19.5%

Where the revenue comes from

Revenue by segments, fiscal 2025.

MedSurg and Neurotechnology$15.6B62%
Orthopaedics$9.5B38%

Superinvestors who own SYK

From each investor's latest 13F filing (what a 13F shows). 5 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Hersh Cohen
ClearBridge Investments
Trimmed $373M0.31%Q2 2026
PRIMECAP Management
PRIMECAP Management Co
Added $213M0.13%Q2 2026
Cliff Asness
AQR Capital Management
Trimmed $150M0.05%Q2 2026
Joel Greenblatt
Gotham Asset Management
Added $40M0.09%Q2 2026
Mario Gabelli
GAMCO Investors
Added $7M0.06%Q2 2026

Insider buying

Open-market purchases by Stryker's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

DateInsiderSharesPriceValue
Feb 24, 2026 Ro Khanna
0$381.84—
Feb 24, 2026 Ro Khanna
0$381.84—
Feb 17, 2026 Ro Khanna
0$369.13—
Feb 17, 2026 Ro Khanna
0$369.13—
Dec 10, 2025 Gilbert Ray Cisneros, Jr.
0$353.84—
Dec 10, 2025 Gilbert Ray Cisneros, Jr.
0$353.84—
Nov 18, 2025 Gilbert Ray Cisneros, Jr.
0$359.53—
Nov 18, 2025 Gilbert Ray Cisneros, Jr.
0$359.53—
Nov 10, 2025 Ro Khanna
0$355.03—
Nov 10, 2025 Ro Khanna
0$355.03—

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when SYK trades at or below it.

$

Free accounts get 3 price alerts. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

What growth does Stryker's stock price imply?

At a market value of $112.2B, Stryker would need its free cash flow to grow about 9% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 9 years its free cash flow grew 13% a year.

Are Stryker insiders buying the stock?

10 open-market insider purchases of SYK in the last 12 months, from SEC Form 4 filings.

Which superinvestors own Stryker?

5 of the superinvestors Investingly tracks hold SYK in their latest 13F, including Hersh Cohen, PRIMECAP Management, Cliff Asness.

Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.